The stock of Standard BioTools Inc (LAB) has gone down by -14.48% for the week, with a 18.12% rise in the past month and a 3.28% rise in the past quarter. The volatility ratio for the week is 7.95%, and the volatility levels for the past 30 days are 7.94% for LAB. The simple moving average for the last 20 days is -4.61% for LAB stock, with a simple moving average of -14.03% for the last 200 days.
Is It Worth Investing in Standard BioTools Inc (NASDAQ: LAB) Right Now?
The 36-month beta value for LAB is also noteworthy at 1.56. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LAB is 360.25M, and at present, short sellers hold a 3.82% of that float. The average trading volume of LAB on December 25, 2024 was 1.81M shares.
LAB) stock’s latest price update
Standard BioTools Inc (NASDAQ: LAB)’s stock price has decreased by -2.14 compared to its previous closing price of 1.87. However, the company has seen a -14.48% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2024-12-19 that SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) — Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43rd Annual J.P.
Analysts’ Opinion of LAB
Many brokerage firms have already submitted their reports for LAB stocks, with TD Cowen repeating the rating for LAB by listing it as a “Buy.” The predicted price for LAB in the upcoming period, according to TD Cowen is $3.50 based on the research report published on April 16, 2024 of the current year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see LAB reach a price target of $3.25. The rating they have provided for LAB stocks is “Buy” according to the report published on April 04th, 2024.
KeyBanc Capital Markets gave a rating of “Overweight” to LAB, setting the target price at $4 in the report published on July 12th of the previous year.
LAB Trading at -2.35% from the 50-Day Moving Average
After a stumble in the market that brought LAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -39.80% of loss for the given period.
Volatility was left at 7.94%, however, over the last 30 days, the volatility rate increased by 7.95%, as shares surge +12.96% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -3.17% lower at present.
During the last 5 trading sessions, LAB fell by -17.19%, which changed the moving average for the period of 200-days by -33.45% in comparison to the 20-day moving average, which settled at $1.9158. In addition, Standard BioTools Inc saw -14.48% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at LAB starting from Black Jeffrey G., who proposed sale 57,971 shares at the price of $2.12 back on Nov 12 ’24. After this action, Black Jeffrey G. now owns shares of Standard BioTools Inc, valued at $123,098 using the latest closing price.
Taich Adam, the Former Officer of Standard BioTools Inc, proposed sale 45,851 shares at $2.00 during a trade that took place back on Sep 09 ’24, which means that Taich Adam is holding shares at $91,725 based on the most recent closing price.
Stock Fundamentals for LAB
Current profitability levels for the company are sitting at:
- -0.82 for the present operating margin
- 0.49 for the gross margin
The net margin for Standard BioTools Inc stands at -0.8. The total capital return value is set at -0.23. Equity return is now at value -69.68, with -24.41 for asset returns.
Based on Standard BioTools Inc (LAB), the company’s capital structure generated 0.11 points at debt to capital in total, while cash flow to debt ratio is standing at -2.34. The debt to equity ratio resting at 0.13. The interest coverage ratio of the stock is -115.98.
Currently, EBITDA for the company is -54.46 million with net debt to EBITDA at 1.04. When we switch over and look at the enterprise to sales, we see a ratio of 3.59. The receivables turnover for the company is 4.41for trailing twelve months and the total asset turnover is 0.23. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.76.
Conclusion
In summary, Standard BioTools Inc (LAB) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
